Praxis Precision Medicines' movement disorder drug shows promise in trials
16/10/2025 12:07
Oct 16 (Reuters) - Praxis Precision Medicines PRAX.O said on Thursday its experimental drug for movement disorder helped improve daily functioning in patients in two late-stage trials. (Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Praxis Precision Medicines
See all newsUS RESEARCH ROUNDUP-Arxis, Cigna, Vylor
Brief: Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Praxis Precision Medicines, Inc. reports results for the quarter ended June 30 - Earnings Summary
Praxis Precision Q2 net loss widens on higher expenses
Brief: Praxis Precision Q2 EPS USD -2.87